Pure Global AI
NCT06009874Recruiting

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction
Mohammad Hussien Tantawy SolimanClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Myocardial Infarction
Drug/Device/Intervention
Dapagliflozin 10mg Tab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mohammad Hussien Tantawy Soliman
Funder
Tanta University
Location
Shibīn Al Kawm, Egypt
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Aug 01, 2026
Enrollment
80 participants
Primary outcome

difference in infarct size,difference in NT-proBNP level

Summary

This study aims to investigate the effect of early administration of DAPA during ischemia and
 before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection
 from HF, and renoprotection from AKI in patients with AMI.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedOld myocardial infarctionSubsequent myocardial infarctionObservation for suspected myocardial infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06009874
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06009874 through Pure Global AI's free database. This phase not specified trial is sponsored by Mohammad Hussien Tantawy Soliman and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.